In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AZ and Merck enter Lynparza alliance; Merck pays $1.6bn up front

Executive Summary

AstraZeneca PLC and Merck & Co. Inc. agreed to co-develop and commercialize AZ’s poly ADP ribose (PARP) inhibitor Lynparza (olaparib) as a monotherapy and in combination with other compounds for various types of cancer. The deal also involves AZ’s Phase III MEK inhibitor selumetinib and the marketed immunotherapies Keytruda (pembrolizumab) (PD-1 antagonist sold by Merck) and Imfinzi (durvalumab) (PD-L1 antagonist sold by AZ).

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies